Organon & Co.
OGNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeOrganon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle. The company carries a $3.61B market cap, placing it firmly in the mid-cap category. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
Market Cap
$3.61B
Beta
1.54
P/E (TTM)
17.63
P/E (Fwd)
3.80
EPS (TTM)
$0.78
EPS (Fwd)
$3.62
ROE
24.0%
ROA
5.7%
Cash
$1.13B
Total Debt
$8.55B
Free CF
$490.8M
52W Change
50.1%
Annual Financials
Cash vs Debt
Where OGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, OGN finished 11.07% above its 150-day moving average ($12.38) and 22.33% above its 200-day moving average ($11.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OGN overbought or oversold?
At the October 20, 2026 close, OGN's RSI(14) was 51.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Organon & Co. carries $8.55B in total debt against $1.13B in cash reserves — debt is roughly 7.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $490.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 24.0%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.17B (2022) to $6.22B (2025).
A beta of 1.54 means OGN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing OGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.